Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer

Journal of Clinical Oncology

Volumn 27, Issue 31, 2009, Pages 5287-5297

  Roy, Roopali ^a   Yang, Jiang ^a   Moses, Marsha A ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AE 941; ANGIOSTAT; BASIC FIBROBLAST GROWTH FACTOR; BATIMASTAT; BMS 27591; DALTEPARIN; DISULFIRAM; ENDOSTATIN; EPIREGULIN; GELATINASE A; GELATINASE B; GENISTEIN; INCB 7839; INCYCLINIDE; INTERSTITIAL COLLAGENASE; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 26; MATRIX METALLOPROTEINASE INHIBITOR; NEU DIFFERENTIATION FACTOR; PCK 3145; PRINOMASTAT; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; STROMELYSIN; TANOMASTAT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; TUMOR MARKER;

ADVANCED CANCER; ANTIANGIOGENIC THERAPY; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER INHIBITION; CELL ADHESION; CELL MIGRATION; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DIAGNOSTIC VALUE; DRUG DESIGN; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HUMAN; KAPOSI SARCOMA; KIDNEY CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS INHIBITION; MULTIPLE MYELOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN DEGRADATION; REVIEW; SOLID TUMOR; ENZYMOLOGY; METABOLISM; NEOPLASM;

HUMANS; MATRIX METALLOPROTEINASES; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 70449732503     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.5556     Document Type: Review

References (152)

1. Nagase H, Visse R, Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69:562-573, 2006
2. Murphy G, Nagase H: Progress in matrix metalloproteinase research. Mol Aspects Med 29: 290-308, 2008
3. Stetler-Stevenson WG: Tissue inhibitors of metalloproteinases in cell signaling: Metalloproteinase-independent biological activities. Sci Signal 1:re6, 2008
4. Harper J, Moses MA: Molecular regulation of tumor angiogenesis: Mechanisms and therapeutic implications. EXS 223-268, 2006
5. Roy R, Zhang B, Moses MA: Making the cut: Protease-mediated regulation of angiogenesis. Exp Cell Res 312:608-622, 2006
6. Cruz-Munoz W, Khokha R: The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci 45:291-338, 2008
7. van Hinsbergh VW, Koolwijk P: Endothelial sprouting and angiogenesis: Matrix metalloproteinases in the lead. Cardiovasc Res 78:203-212, 2008
8. Matrisian LM, Wright J, Newell K, et al: Matrix-degrading metalloproteinases in tumor progression. Princess Takamatsu Symp 24:152-161, 1994
9. Bode W, Maskos K: Structural studies on MMPs and TIMPs. Methods Mol Biol 151:45-77, 2001
10. Stone AL, Kroeger M, Sang QX: Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase-containing proteins. J Protein Chem 18:447-465, 1999
11. Edwards DR, Handsley MM, Pennington CJ: The ADAM metalloproteinases. Mol Aspects Med 29:258-289, 2008
12. Murphy G: The ADAMs: Signaling scissors in the tumour microenvironment. Nat Rev Cancer 8:929-941, 2008
13. Apte SS: A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: The ADAMTS family. Int J Biochem Cell Biol 36:981-985, 2004
14. Xu J, Rodriguez D, Petitclerc E, et al: Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 154:1069-1079, 2001
15. Koshikawa N, Giannelli G, Cirulli V, et al: Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 148:615-624, 2000
16. Noe V, Fingleton B, Jacobs K, et al: Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114:111-118, 2001
17. Maretzky T, Reiss K, Ludwig A, et al: ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci U S A 102:9182-9187, 2005
18. Ratnikov BI, Rozanov DV, Postnova TI, et al: An alternative processing of integrin alpha(v) subunit in tumor cells by membrane type-1 matrix metalloproteinase. J Biol Chem 277:7377-7385, 2002
19. Baciu PC, Suleiman EA, Deryugina EI, et al: Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-alphav integrin regulates cross-talk between alphavbeta3 and alpha2beta1 integrins in breast carcinoma cells. Exp Cell Res 291:167-175, 2003
20. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454, 2002
21. Illman SA, Lehti K, Keski-Oja J, et al: Epilysin (MMP-28) induces TGF-beta mediated epithelial to mesenchymal transition in lung carcinoma cells. J Cell Sci 119:3856-3865, 2006
22. Lochter A, Galosy S, Muschler J, et al: Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 139:1861-1872, 1997
23. Radisky DC, Levy DD, Littlepage LE, et al: Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436: 123-127, 2005
24. Noel A, Jost M, Maquoi E: Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol 19:52-60, 2008
25. Chandler S, Cossins J, Lury J, et al: Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factoralpha fusion protein. Biochem Biophys Res Commun 228:421-429, 1996
26. Haro H, Crawford HC, Fingleton B, et al: Matrix metalloproteinase-7- dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest 105:143-150, 2000
27. Black RA, Rauch CT, Kozlosky CJ, et al: A metalloproteinase disintegrin that releases tumournecrosis factor-alpha from cells. Nature 385:729-733, 1997
28. Benaud C, Dickson RB, Thompson EW: Roles of the matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res Treat 50:97-116, 1998
29. Thrailkill KM, Quarles LD, Nagase H, et al: Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. Endocrinology 136:3527-3533, 1995
30. Fowlkes JL, Enghild JJ, Suzuki K, et al: Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem 269:25742-25746, 1994
31. Loechel F, Wewer UM: Activation of ADAM 12 protease by copper. FEBS Lett 506:65-68, 2001
32. Manes S, Mira E, Barbacid MM, et al: Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem 272:25706-25712, 1997
33. Suzuki M, Raab G, Moses MA, et al: Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem 272:31730-31737, 1997
34. Schafer B, Marg B, Gschwind A, et al: Distinct ADAM metalloproteinases regulate G proteincoupled receptor-induced cell proliferation and survival. J Biol Chem 279:47929-47938, 2004
35. Sahin U, Weskamp G, Kelly K, et al: Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164:769-779, 2004
36. Ongusaha PP, Kwak JC, Zwible AJ, et al: HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res 64:5283-5290, 2004
37. McGowan PM, Ryan BM, Hill AD, et al: ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res 13:2335-2343, 2007
38. Blobel CP: ADAMs: Key components in EGFR signaling and development. Nat Rev Mol Cell Biol 6:32-43, 2005
39. Kenny PA, Bissell MJ: Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 117:337-345, 2007
40. Houck KA, Leung DW, Rowland AM, et al: Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267:26031-26037, 1992
41. Bergers G, Brekken R, McMahon G, et al: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737-744, 2000
42. Whitelock JM, Murdoch AD, Iozzo RV, et al: The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 271:10079-10086, 1996
43. Birkedal-Hansen H: Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 7:728-735, 1995
44. Unemori EN, Ferrara N, Bauer EA, et al: Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 153:557-562, 1992
45. Lamoreaux WJ, Fitzgerald ME, Reiner A, et al: Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 55:29-42, 1998
46. Fang J, Shing Y, Wiederschain D, et al: Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A 97:3884-3889, 2000
47. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, et al: Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 274:29568-29571, 1999
48. Dong Z, Kumar R, Yang X, et al: Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88:801-810, 1997
49. Wen W, Moses MA, Wiederschain D, et al: The generation of endostatin is mediated by elastase. Cancer Res 59:6052-6056, 1999
50. Zhang B, Cao X, Liu Y, et al: Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer 83:1-10, 2008
51. Wu ZS, Wu Q, Yang JH, et al: Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 122:2050-2056, 2008
52. Fernandez CA, Yan L, Louis G, et al: The matrix metalloproteinase-9/ neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 11:5390-5395, 2005
53. La Rocca G, Pucci-Minafra I, Marrazzo A, et al: Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 90:1414-1421, 2004
54. Ranuncolo SM, Armanasco E, Cresta C, et al: Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 106:745-751, 2003
55. Roy R, Wewer UM, Zurakowski D, et al: ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 279:51323-51330, 2004
56. McGowan PM, McKiernan E, Bolster F, et al: ADAM-17 predicts adverse outcome in patients with breast cancer. Ann Oncol 19:1075-1081, 2008
57. Poola I, DeWitty RL, Marshalleck JJ, et al: Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med 11:481-483, 2005
58. Tian M, Cui YZ, Song GH, et al: Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 241:1-11, 2008
59. Yokoyama M, Ochi K, Ichimura M, et al: Matrix metalloproteinase-2 in pancreatic juice for diagnosis of pancreatic cancer. Pancreas 24:344-347, 2002
60. Kuhlmann KF, van Till JW, Boermeester MA, et al: Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16:886-891, 2007
61. Jones LE, Humphreys MJ, Campbell F, et al: Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: Increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 10:2832-2845, 2004
62. Grutzmann R, Luttges J, Sipos B, et al: ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer 90:1053-1058, 2004
63. Jumper C, Cobos E, Lox C: Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir Med 98:173-177, 2004
64. Koc M, Ediger D, Budak F, et al: Matrix metalloproteinase-9 (MMP-9) elevated in serum but not in bronchial lavage fluid in patients with lung cancer. Tumori 92:149-154, 2006
65. Liu D, Nakano J, Ishikawa S, et al: Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. Lung Cancer 58:384-391, 2007
66. Su L, Zhou W, Park S, et al: Matrix metalloproteinase-1 promoter polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 14:567-570, 2005
67. Sauter W, Rosenberger A, Beckmann L, et al: Matrix metalloproteinase 1 (MMP1) is associated with early-onset lung cancer. Cancer Epidemiol Biomarkers Prev 17:1127-1135, 2008
68. Papathoma AS, Petraki C, Grigorakis A, et al: Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res 20:2009-2013, 2000
69. Gerhards S, Jung K, Koenig F, et al: Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology 57:675-679, 2001
70. Roy R, Louis G, Loughlin KR, et al: Tumor-specific urinary matrix metalloproteinase fingerprinting: Identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 14:6610-6617, 2008
71. Moses MA, Wiederschain D, Loughlin KR, et al: Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58:1395-1399, 1998
72. Sier CF, Casetta G, Verheijen JH, et al: Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: A comparison with clinically used tumor markers. Clin Cancer Res 6:2333-2340, 2000
73. Eissa S, Swellam M, el-Mosallamy H, et al: Diagnostic value of urinary molecular markers in bladder cancer. Anticancer Res 23:4347-4355, 2003
74. Hilska M, Roberts PJ, Collan YU, et al: Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 121:714-723, 2007
75. Langenskiold M, Holmdahl L, Falk P, et al: Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer. Int J Colorectal Dis 20:245-252, 2005
76. Cho YB, Lee WY, Song SY, et al: Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer. Hum Pathol 38:1603-1610, 2007
77. Tutton MG, George ML, Eccles SA, et al: Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer 107:541-550, 2003
78. Maurel J, Nadal C, Garcia-Albeniz X, et al: Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer 121:1066-1071, 2007
79. Baker EA, Leaper DJ: The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: Relationship to tumour pathology. Eur J Cancer 39:981-988, 2003
80. Leeman MF, McKay JA, Murray GI: Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol 55:758-762, 2002
81. Lengyel E, Schmalfeldt B, Konik E, et al: Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 82:291-298, 2001
82. Kamat AA, Fletcher M, Gruman LM, et al: The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 12:1707-1714, 2006
83. Perigny M, Bairati I, Harvey I, et al: Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol 129:226-231, 2008
84. Adley BP, Gleason KJ, Yang XJ, et al: Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: High level expression in clear cell carcinoma. Gynecol Oncol 112:319-324, 2009
85. Tanaka Y, Miyamoto S, Suzuki SO, et al: Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 11:4783-4792, 2005
86. Morgia G, Falsaperla M, Malaponte G, et al: Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 33:44-50, 2005
87. Miyake H, Muramaki M, Kurahashi T, et al: Expression of potential molecular markers in prostate cancer: Correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol October 9, 2008 [epub ahead of print]
88. Trudel D, Fradet Y, Meyer F, et al: Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: Identification of patients with poor prognosis by immunohistochemistry. Hum Pathol 39:731-739, 2008
89. Fritzsche FR, Jung M, Xu C, et al: ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis. Virchows Arch 449:628-636, 2006
90. Fritzsche FR, Jung M, Tolle A, et al: ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol 54:1097-1106, 2008
91. Sawaya RE, Yamamoto M, Gokaslan ZL, et al: Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Exp Metastasis 14:35-42, 1996
92. Jaalinoja J, Herva R, Korpela M, et al: Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. J Neurooncol 46:81-90, 2000
93. Rao JS, Yamamoto M, Mohaman S, et al: Expression and localization of 92 kDa type IV collagenase/ gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis 14:12-18, 1996
94. Choe G, Park JK, Jouben-Steele L, et al: Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res 8:2894-2901, 2002
95. Friedberg MH, Glantz MJ, Klempner MS, et al: Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer 82:923-930, 1998
96. Smith ER, Zurakowski D, Saad A, et al: Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 14:2378-2386, 2008
97. Pories SE, Zurakowski D, Roy R, et al: Urinary metalloproteinases: Noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev 17:1034-1042, 2008
98. Zucker S, Hymowitz M, Conner C, et al: Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues: Clinical and experimental applications. Ann N Y Acad Sci 878:212-227, 1999
99. Tetu B, Brisson J, Wang CS, et al: The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res R28:1-9, 2006
100. Schutz A, Schneidenbach D, Aust G, et al: Differential expression and activity status of MMP-1, MMP-2 and MMP-9 in tumor and stromal cells of squamous cell carcinomas of the lung. Tumour Biol 23:179-184, 2002
101. Ohtsuka T, Shiomi T, Shimoda M, et al: ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. Int J Cancer 118:263-273, 2006
102. Frohlich C, Albrechtsen R, Dyrskjot L, et al: Molecular profiling of ADAM12 in human bladder cancer. Clin Cancer Res 12:7359-7368, 2006
103. Waas ET, Wobbes T, Lomme RM, et al: Plasma gelatinase activity does not reflect disease activity after operation for colorectal cancer. Oncology 68:256-262, 2005
104. Schmalfeldt B, Prechtel D, Harting K, et al: Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 7:2396-2404, 2001
105. Omura GA, Brady MF, Homesley HD, et al: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol 9:1138-1150, 1991
106. Sillanpaa S, Anttila M, Voutilainen K, et al: Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol 104:296-303, 2007
107. Wood M, Fudge K, Mohler JL, et al: In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 15:246-258, 1997
108. Sauer CG, Kappeler A, Spath M, et al: Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients. Virchows Arch 444:518-526, 2004
109. Riddick AC, Shukla CJ, Pennington CJ, et al: Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer 92:2171-2180, 2005
110. Kuniyasu H, Ukai R, Johnston D, et al: The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy. Clin Cancer Res 9:2185-2194, 2003
111. Smith ER, Manfredi M, Scott RM, et al: A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: Case report. Neurosurgery 60:E1148-E1149, 2007; discussion E1149, 2007
112. Jung K, Laube C, Lein M, et al: Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin Chem 44:1060-1062, 1998
113. Makowski GS, Ramsby ML: Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma. Anal Biochem 322:283-286, 2003
114. Rouy D, Ernens I, Jeanty C, et al: Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem 338:294-298, 2005
115. Zucker S, Cao J: Measurement of matrix metalloproteinases in serum of patients with melanoma: Snarled in technical pitfalls. Clin Cancer Res 11:5069-5070, 2005
116. Robins HI, O'Neill A, Gilbert M, et al: Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: A phase II ECOG trial. Cancer Chemother Pharmacol 62:227-233, 2008
117. Sideras K, Schaefer PL, Okuno SH, et al: Low-molecularity-weight heparin in patients with advanced cancer: A phase III clinical trial. Mayo Clin Proc 81:758-767, 2006
118. Loprinzi CL, Levitt R, Barton DL, et al: Evaluation of shark cartilage in patients with advanced cancer: A North Central Cancer Treatment Group trial. Cancer 104:176-182, 2005
119. Lu C, Lee JJ, Komaki R, et al: A phase III study of AE-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303). J Clin Oncol 25:391S (suppl 18S abstr 7527)
120. Batist G, Patenaude F, Champagne P, et al: Neovastat (AE-941) in refractory renal cell carcinoma patients: Report of a phase II trial with two dose levels. Ann Oncol 13:1259-1263, 2002
121. Betz M, Huxley P, Davies SJ, et al: 1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. Eur J Biochem 247:356-363, 1997
122. Saghatelian A, Jessani N, Joseph A, et al: Activity-based probes for the proteomic profiling of metalloproteases. Proc Natl Acad Sci U S A 101: 10000-10005, 2004
123. Hidalgo M, Eckhardt SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93:178-193, 2001
124. Miller KD, Saphner TJ, Waterhouse DM, et al: A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res 10:1971-1975, 2004
125. Dublanchet AC, Ducrot P, Andrianjara C, et al: Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors. Bioorg Med Chem Lett 15:3787-3790, 2005
126. Chen JM, Nelson FC, Levin JI, et al: Structurebased design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design. J Am Chem Soc 122:9648-9654, 2000
127. Golub LM, Ramamurthy NS, McNamara TF, et al: Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 2:297-321, 1991
128. Acharya MR, Venitz J, Figg WD, et al: Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist Updat 7:195-208, 2004
129. Sapadin AN, Fleischmajer R: Tetracyclines: Nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54:258-265, 2006
130. Brown S, Bernardo MM, Li Z, et al: Potent and selective mechanism-based inhibition of gelatinases. J Am Chem Soc 122:6799-6800, 2000
131. Kleifeld O, Kotra LP, Gervasi DC, et al: X-ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to a highly selective mechanism-based inhibitor: Comparison with the latent and active forms of the enzyme. J Biol Chem 276:17125-17131, 2001
132. Kruger A, Arlt MJ, Gerg M, et al: Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res 65:3523-3526, 2005
133. Ikejiri M, Bernardo MM, Meroueh SO, et al: Design, synthesis, and evaluation of a mechanismbased inhibitor for gelatinase A. J Org Chem 70: 5709-5712, 2005
134. Moss ML, Bartsch JW: Therapeutic benefits from targeting of ADAM family members. Biochemistry 43:7227-7235, 2004
135. Liu X, Fridman JS, Wang Q, et al: Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. Cancer Biol Ther 5:648-656, 2006
136. Fridman JS, Caulder E, Hansbury M, et al: Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res 13:1892-1902, 2007
137. Fernandez CA, Butterfield C, Jackson G, et al: Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): Loop 6 is a novel angiogenesis inhibitor. J Biol Chem 278: 40989-40995, 2003
138. Seo DW, Li H, Guedez L, et al: TIMP-2 mediated inhibition of angiogenesis: An MMP-independent mechanism. Cell 114:171-180, 2003
139. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295:2387-2392, 2002
140. Fingleton B: MMPs as therapeutic targets - still a viable option? Semin Cell Dev Biol 19:61-68, 2008
141. Bergers G, Javaherian K, Lo KM, et al: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808-812, 1999
142. Witty JP, Lempka T, Coffey RJ Jr, et al: Decreased tumor formation in 7,12-dimethylbenzanthracenetreated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Cancer Res 55:1401-1406, 1995
143. Balbin M, Fueyo A, Tester AM, et al: Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 35:252-257, 2003
144. Acuff HB, Sinnamon M, Fingleton B, et al: Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. Cancer Res 66:7968-7975, 2006
145. Yang W, Arii S, Gorrin-Rivas MJ, et al: Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. Cancer 91:1277-1283, 2001
146. Coussens LM, Tinkle CL, Hanahan D, et al: MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103:481-490, 2000
147. Overall CM, Kleifeld O: Tumour microenvironment - opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6:227-239, 2006
148. Cornelius LA, Nehring LC, Harding E, et al: Matrix metalloproteinases generate angiostatin: Effects on neovascularization. J Immunol 161:6845-6852, 1998
149. Ferreras M, Felbor U, Lenhard T, et al: Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 486: 247-251, 2000
150. McCawley LJ, Crawford HC, King LE Jr, et al: A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res 64:6965-6972, 2004
151. Parks WC, Wilson CL, Lopez-Boado YS: Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4:617-629, 2004
152. Bremer C, Tung CH, Weissleder R: In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 7:743-748, 2001